Meeting
2022 ASCO Annual Meeting
Real-world effectiveness of first-line maintenance olaparib in women with BRCA-mutated advanced ovarian cancer: U.S. retrospective cohort study.
Authors
Ramez Nassef Eskander
UC San Diego Moores Cancer Center, San Diego, CA
Ramez Nassef Eskander , Naufil Alam , Grainne H. Long , Ozan Ozgoren , Will Ambler , Stephanie Volpe , Kathleen N. Moore
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5518)
DOI
10.1200/JCO.2022.40.16_suppl.5518
Abstract #
5518
Poster Bd #
397
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.
First Author: Cara Amanda Mathews
Poster
2019 ASCO Annual Meeting
Adverse events (AEs) with maintenance olaparib in newly diagnosed patients (pts) with advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Phase III SOLO1 trial.
First Author: Nicoletta Colombo
Poster
2022 ASCO Annual Meeting
Efficacy of maintenance olaparib plus bevacizumab in patients with newly diagnosed advanced ovarian cancer according to BRCA mutation genotype in the phase III PAOLA-1/ENGOT-ov25 trial.
First Author: Sana Intidhar Labidi-Galy
Poster
2022 ASCO Annual Meeting
Quality of life in patients with advanced high-grade ovarian cancer (HGOC) receiving maintenance therapies after first-line (1L) chemotherapy in the randomized phase III PAOLA-1/ENGOT-ov25 trial (NCT02477644).
First Author: Jean Emmanuel Kurtz